Effect of Itraconazole or Rifampin on Zilurgisertib Pharmacokinetics When Administered Orally in Healthy Participants
Sign Up to like & getrecommendations! Published in 2025 at "Clinical Pharmacology in Drug Development"
DOI: 10.1002/cpdd.1553
Abstract: Zilurgisertib is an oral, activin receptor‐like kinase 2 (ALK2) inhibitor being developed for the treatment of patients with fibrodysplasia ossificans progressiva. In vitro metabolism studies suggest zilurgisertib is primarily eliminated via cytochrome P450 (CYP) 3A4/5‐mediated… read more here.
Keywords: healthy participants; concomitant administration; drug; zilurgisertib ... See more keywords
The activin receptor-like kinase-2 inhibitor zilurgisertib (INCB000928) as monotherapy or with ruxolitinib in patients with anemia due to myelofibrosis: Phase 1/2 study final results
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-3795
Abstract: Background: Hepcidin dysregulation contributes to anemia of chronic inflammation observed in several malignancies, and hepcidin levels are elevated in myelofibrosis (MF). It has been proposed that activin receptor-like kinase-2 (ALK2 [ie, ACVR1]) contributes to MF-associated… read more here.
Keywords: treatment; tgc; tga tgb; zilurgisertib ... See more keywords